- Went public, Oct 2024
- Raised $17M funding round, Mar 2025
- Raised $3.5M funding round, Apr 2026
About
Polyrizon is a biotech company focused on the development and commercialization of innovative intranasal products.
Polyrizons Capture & Contain (C&C) platform is based on a natural 3D polymeric network tailored to optimally adhere to the nasal mucosal surface. The polymeric network creates a physical barrier that captures and contains biological contaminants, preventing their penetration. The C&C platform can be readily adapted for a wide range of applications to protect the human body from airborne contaminants such as allergens, viruses, and molds.
The companys Trap & Target (T&T) platform delivery technology is designed to allow a long residence time and intimate contact with the mucosal tissue for highly effective targeted delivery of medicines. It can be tailored to address the specific requirements of different molecules for improved therapeutic effect.
Funding history · 8 rounds · $27.0M total
Q&A
- When did Polyrizon become a public company and on which exchange?
- Polyrizon became public on NASDAQ in October 2024.
- What was the amount raised in Polyrizon's Initial Public Offering?
- Polyrizon's Initial Public Offering in October 2024 raised $4.2 million.
- What is Polyrizon's primary focus as a biotech company?
- Polyrizon is a biotech company focused on the development and commercialization of innovative intranasal products.
- What is Polyrizon's Capture & Contain (C&C) platform designed to do?
- Polyrizon's Capture & Contain (C&C) platform creates a physical barrier using a natural 3D polymeric network to capture and contain biological contaminants on the nasal mucosal surface, preventing their penetration.
- What is the purpose of Polyrizon's Trap & Target (T&T) platform delivery technology?
- The Trap & Target (T&T) platform delivery technology is designed to allow a long residence time and intimate contact with mucosal tissue for effective targeted delivery of medicines, adaptable for different molecules.
- What was a significant funding event for Polyrizon in March 2025?
- In March 2025, Polyrizon announced the closing of a $17.0 million private placement.
- What was a key development for Polyrizon's NASARIX™ Allergy Blocker in May 2026?
- In May 2026, Polyrizon secured its first U.S. clinical site for the NASARIX™ Allergy Blocker clinical trial, advancing towards human clinical trials.
- What patent development did Polyrizon announce in May 2026?
- In May 2026, Polyrizon announced a U.S. patent expansion for its Intranasal Drug Delivery Platform.
- What strategic move did Polyrizon announce in March 2026 regarding Colugo?
- In March 2026, Polyrizon announced its intention to acquire up to a 20% stake in Colugo, a developer of advanced eVTOL drones.
- What was the outcome of Polyrizon's biocompatibility program for NASARIX™ in July 2026?
- In July 2026, Polyrizon announced successful results for its NASARIX™ Biocompatibility Program, supporting its advancement towards the first-in-human clinical trial.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | polyrizon-biotech.com/ |
|---|---|
| linkedin.com/company/202428 |
Identifiers & details
| Founded | 2020-3 |
|---|---|
| Employees (exact) | 8 |
| Market cap | $8.8M |
| Status reason | Public on NASDAQ on Oct 2024; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2024-10 | $4.2M |